MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Karyopharm Therapeutics Inc

Chiusa

SettoreSettore sanitario

3.74 -2.86

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.49

Massimo

3.82

Metriche Chiave

By Trading Economics

Entrata

1.3M

-31M

Vendite

-8.2M

31M

EPS

-0.24

Margine di Profitto

-100.779

Dipendenti

279

EBITDA

972K

-20M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+1290.41% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

31M

Apertura precedente

6.6

Chiusura precedente

3.74

Notizie sul Sentiment di mercato

By Acuity

50%

50%

166 / 386 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Karyopharm Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 apr 2025, 23:04 UTC

Notizie principali

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 apr 2025, 22:40 UTC

I principali Market Mover

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 apr 2025, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 apr 2025, 18:51 UTC

Acquisizioni, Fusioni, Takeovers

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

4 apr 2025, 00:00 UTC

Notizie principali

Resistance Is Futile, Make a Deal: Trump's Tariff Message to the World -- WSJ

3 apr 2025, 23:43 UTC

Discorsi di Mercato

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 apr 2025, 23:41 UTC

Discorsi di Mercato

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 apr 2025, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 21:43 UTC

Notizie principali
Utili

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 apr 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

3 apr 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

3 apr 2025, 20:43 UTC

Discorsi di Mercato

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 apr 2025, 20:34 UTC

Notizie principali

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 apr 2025, 20:23 UTC

Notizie principali

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 apr 2025, 19:55 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2025, 19:55 UTC

Discorsi di Mercato

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 apr 2025, 19:21 UTC

Discorsi di Mercato

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 apr 2025, 19:15 UTC

Discorsi di Mercato

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 apr 2025, 18:45 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:45 UTC

Discorsi di Mercato

Gold Drops In Tariff Fallout -- Market Talk

3 apr 2025, 18:39 UTC

Discorsi di Mercato

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 apr 2025, 18:38 UTC

Notizie principali

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 18:30 UTC

Notizie principali

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 apr 2025, 18:20 UTC

Discorsi di Mercato

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 apr 2025, 18:18 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:17 UTC

Discorsi di Mercato

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 apr 2025, 18:04 UTC

Discorsi di Mercato

US Sees More Job Openings in Construction, Transportation -- Market Talk

Confronto tra pari

Modifica del prezzo

Karyopharm Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

1290.41% in crescita

Previsioni per 12 mesi

Media 53.67 USD  1290.41%

Alto 105 USD

Basso 15 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Karyopharm Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

5

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.9501 / 7.66Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

166 / 386 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$